MAPK Pathway

Similar documents
Biol403 MAP kinase signalling

The elements of G protein-coupled receptor systems

RAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.

Cell Signaling part 2

KEY CONCEPT QUESTIONS IN SIGNAL TRANSDUCTION

Receptor mediated Signal Transduction

Antibodies. Product Name Cat. No. Size. GH (Growth Hormone) Antibody µg, 100 µg GM-CSF Antibody µg, 100 µg

Cell Signaling II: A circuitous pursuit

Computational Biology I LSM5191

Signaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research

MCB*4010 Midterm Exam / Winter 2008

Lecture 7: Signaling Through Lymphocyte Receptors

Cellular Signaling Pathways. Signaling Overview

Signaling Through Immune System Receptors (Ch. 7)

blood mononuclear cells were stained with AAD, annexin, CD3, CD4, CD25, LAP and specific

G-Protein Signaling. Introduction to intracellular signaling. Dr. SARRAY Sameh, Ph.D

1. Activated receptor tyrosine kinases (RTKs) phosphorylates themselves

The Tissue Engineer s Toolkit

Regulation of cell function by intracellular signaling

Principles of Genetics and Molecular Biology

Growth and Differentiation Phosphorylation Sampler Kit

Electrical Stimulation Control Nerve Regeneration via the p38 Mitogen-activated Protein Kinase and CREB

Enzyme-coupled Receptors. Cell-surface receptors 1. Ion-channel-coupled receptors 2. G-protein-coupled receptors 3. Enzyme-coupled receptors

Phospho-AKT Sampler Kit

Chapter 6: Cancer Pathways. Other Pathways. Cancer Pathways

Signal Transduction SS Gerhild van Echten-Deckert

Revision. camp pathway

MEK1 Assay Kit 1 Catalog # Lot # 16875

Propagation of the Signal


Supplementary Material. Part I: Sample Information. Part II: Pathway Information

Map kinase signaling pathways and hematologic malignancies

Signal Transduction Pathways. Part 2

Chapter 15: Signal transduction

INTERACTION DRUG BODY

Signal Transduction I

Determination Differentiation. determinated precursor specialized cell

Signal Transduction: G-Protein Coupled Receptors

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION

Effects of Second Messengers

Genetics and Cancer Ch 20

An Egf Signaling Map in Pathway Logic

Cell cycle, signaling to cell cycle, and molecular basis of oncogenesis

Protein kinases are enzymes that add a phosphate group to proteins according to the. ATP + protein OH > Protein OPO 3 + ADP

Applications of Rewriting Logic in Biology

Table S1: Data-generating Model:

Biosignals, Chapter 8, rearranged, Part I

Chapter 20. Cell - Cell Signaling: Hormones and Receptors. Three general types of extracellular signaling. endocrine signaling. paracrine signaling

Intracellular signalling pathways activated by leptin by Gema FRUHBECK. Presentation by Amnesiacs Anonymous

Part I => CARBS and LIPIDS. 1.7 Signal Transduction 1.7a Endocrine Hormones 1.7b Hormone Receptors

THE HALLMARKS OF CANCER

* Kyoto Encyclopedia of Genes and Genomes.

Using Pathway Logic to Integrate Signal Transduction and Gene Expression Data

ONCOGENES. Michael Lea

Molecular Cell Biology - Problem Drill 19: Cell Signaling Pathways and Gene Expression

Protein tyrosine kinase signaling

What would you observe if you fused a G1 cell with a S cell? A. Mitotic and pulverized chromosomes. B. Mitotic and compact G1 chromosomes.

Nature Structural & Molecular Biology: doi: /nsmb.3218

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

RAW264.7 cells stably expressing control shrna (Con) or GSK3b-specific shrna (sh-

Kevin R. Fox, MD Rena Rowan Breast Center Abramson Cancer Center University of Pennsylvania Perelman School of MedicineR

Apoptosis Oncogenes. Srbová Martina

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Signal transduction and protein kinase inhibitors. Feng Qian ( 钱峰 )

INTRODUCTION. Induction of Monocyte Chemoattractant Protein-1 (MCP-1) Expression by Angiotensin II (AngII) in the Pancreatic Islets and Beta Cells

Cell Cyc Cell Cy l c e

Genetics of Cancer Lecture 32 Cancer II. Prof. Bevin Engelward, MIT Biological Engineering Department

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

International Immunopharmacology 4 (2004) Review article. John J. Haddad*

number Done by Corrected by Doctor Maha Shomaf

Computational Systems Biology: Biology X

Enzymes Part III: regulation II. Dr. Mamoun Ahram Summer, 2017

w ª wy xvwz A ª vw xvw P ª w} xvw w Æ w Æ V w,x Æ w Æ w Æ y,z Æ { Æ y,z, w w w~ w wy}æ zy Æ wyw{ xæ wz w xywæ xx Æ wv Æ } w x w x w Æ w Æ wy} zy Æ wz

Lecture 8 Neoplasia II. Dr. Nabila Hamdi MD, PhD

Phospholipase C γ Prof. Graham Carpenter

Negative feedback regulation of the ERK1/2 MAPK pathway

Principles of cell signaling Lecture 4

How do pleiotropic kinase hubs mediate specific signaling by TNFR superfamily members?

Lecture 15. Signal Transduction Pathways - Introduction

Understanding Signaling Pathways by Modifying Sensitivity to PLX4720 in B-RAF V600E Melanoma

I. Top scoring maps. 1.IFN gamma signaling

Protein kinases a CRASH course. Michael Freissmuth Institute of Pharmacology

Biochemie 4. Cell communication - GPCR

What causes cancer? Physical factors (radiation, ionization) Chemical factors (carcinogens) Biological factors (virus, bacteria, parasite)

INTRACELLULAR SIGNALLING

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS

Protein regulation Protein motion

Biol220 Cell Signalling Cyclic AMP the classical secondary messenger

Chapter 18- Oncogenes, tumor suppressors & Cancer

Bio-Plex Pro Cell Signaling Assays

Supplementary Materials for

TransCon CNP: Preliminary Phase 1 Data. November 28, 2018

Cell Biology Lecture 9 Notes Basic Principles of cell signaling and GPCR system

Control of Cell Proliferation by Peptide Growth Factors. Autocrine Growth Factor Production Causes Malignant Transformation?

Post-translational modifications of proteins in gene regulation under hypoxic conditions

Cell Biology (BIOL 4374 and BCHS 4313) Third Exam 4/24/01

Vets 111/Biov 111 Cell Signalling-2. Secondary messengers the cyclic AMP intracellular signalling system

Cell signaling. How do cells receive and respond to signals from their surroundings?

Modulation of the HGF/c-Met/Akt and p38 cell signaling pathways by 3,3 -diindolylmethane in MDA-MB-231 breast cancer cells. Holly Lynn Nicastro

The interaction between mixed-lineage kinase 3 and the tumor suppressor protein merlin

Transcription:

MAPK Pathway Mitogen-activated protein kinases (MAPK) are proteins that are serine/ threonine specific kinases which are activated by a wide range of stimuli including proinflammatory cytokines, growth factors, mitogens, osmotic stress, heat shock etc. These proteins function in a signaling cascade are activated upon ligand binding to a cell surface receptor activating several MAP/ER kinases, which in turn phosphorylate their respective substrates. These events thereby regulate various cellular activities, such as gene expression, mitosis, differentiation, proliferation, and cell survival/apoptosis. Upon the extracellular mitogen binding to the ligand, Ras a GTPase exchanges GDP for GTP. This in turn initializes a cascade activating MAP3K (Raf) which in turn activates MAP2K which activates MAPK. This MAPK can activate a number of transcription factors which control key processes in the cell. For example epidermal growth factor (EGF) binds the EGFR which activates the tyrosine kinase activity of the EGFR (receptor). Grb2 and SH2 domain containing proteins recognize phosphorylated residues along with a guanine nucleotide exchange factor SOS, and binds to the EGFR. GDP is then swapped for GTP which binds Ras to make it active. Ras activates Raf which can phosphorylate and activate MEK1 and MEK2 which in turn activate MAPK. MAPK regulates a number of transcription factors including c-myc, CREB, C-Fos etc. All these regulate expression of a number of genes involved in apoptosis, differentiation, cancer etc. Defects in the regulation of this pathway can lead to uncontrolled growth in cells,leading to cancer. Over the last decade, important advances have been made in developing novel agents that modulate key proteins in this pathway culminating in the approval by the FDA of Sorafenib (Nexavar ) for the treatment of advanced renal carcinoma. Therapeutic advances in this area should continue for many years to come. MAPK Pathway 155 S. Milipitas Blvd, Milipitas, CA 95035 T: 408-493-1800 F: 408-493-1801 Toll Free: 800-891-9699 (US Only)

Antibodies ASK1/MAPKKK5 Antibody 3128 100 µg cdc/rac Blocking Peptide 3080BP 50 µg cdc42/rac Antibody 3080 30 µg, 100 µg c-jun antibody 3009 30 µg, 100 µg c-jun Antibody 3702 100 µg Erk1/2 MAPK Antibody 3085 100 µg Erk2 Antibody 3442 100 µg Erk5 Antibody 3397 100 µg IL-1 alpha Antibody 5125 30 µg, 100 µg IL-1 beta Antibody 5128 30 µg, 100 µg IL-1 beta Antibody 5129 30 µg, 100 µg IRAK-4 Antibody 3580 100 µg JIK Antibody 3784 100 µl JIP-1 Antibody 3664 30 µg, 100 µg JNK Antibody 3701 30 µg, 100 µg MAPKAPK-2 Antibody 3100 30 µg, 100 µg MAPKAPK-2 Blocking Peptide 3100BP 50 µg Mek1 Antibody 3196 100 µg Mek1/2 Antibody 3518 100 µl MKK3 Antibody 3285 100 µg MLK3 Antibody 3430 100 µg NIK Antibody 3193R 30 µg, 100 µg p38 MAP Kinase Antibody 3114 30 µg, 100 µg p38 MAP Kinase Blocking Peptide 3114BP 50 µg p42/44 MAPK Antibody 3542 100 µg p70 S6 Kinase Antibody 3485 100 µg PAK1 Antibody 3248 100 µg PAK2 Antibody 3443 30 µg, 100 µg PAK2 Blocking Peptide 3443BP 50 µg PAK3 Antibody 3686 30 µg, 100 µg PAK3 Blocking Peptide 3686BP 50 µg PAK4 Antibody 3444 30 µg, 100 µg PAK4 Blocking Peptide 3444BP 50 µg PAK5/PAK7 Antibody 3928 30 µg, 100 µg PAK5/PAK7 Blocking Peptide 3928-BP50 50 µg PAK6 Antibody 3927 30 µg, 100 µg PAK6 Blocking Peptide 3927BP 50 µg PDGF-BB Antibody 5488 30 µg, 200 µg PDGF-BB Antibody 5489 30 µg, 100 µg Phospho-c-Jun (Ser73) Antibody 3502 100 µg Phospho-Elk-1 Antibody 3388 100 µg 2

Antibodies Phospho-Erk1/2 Antibody 3441 100 µg Phospho-JKK1/SEK1/MKK4 Antibody 3478 100 µg Phospho-JNK/SAPK Antibody 3589 100 µg Phospho-MAPKAPK-2 Antibody 3434 100 µg Phospho-Mek1/2 Antibody 3519 100 µl Phospho-MSK1 Antibody 3278 100 µg Phospho-p38 MAPK Antibody 3438 100 µg Phospho-p70 S6 Kinase Antibody 3505 100 µg Phospho-Raf Antibody 3504 100 µg Raf1 Antibody 3116 30 µg, 100 µg RIP Antibody 3279 30 µg, 100 µg RSK2 Antibody 3546 100 µg SPHKAP Antibody 6656 30 µg, 100 µg TAB1 Antibody 3682 100 µg TANK Polyclonal Antibody 3348 30 µg, 100 µg TAOK1 Antibody 3776 100 µl TAOK1 Antibody 3776R 30 µg, 100 µg TNF-alpha Antibody 3053R 30 µg, 100 µg TNF-beta Antibody 5345 100 µg TRAF6 Antibody 3566R 30 µg, 100 µg Enzymes ASK1, Active 7710 5 μg CD40Ligand/TRAP, human recombi nant 4014 10 μg, 50 μg, 1 mg CD40Ligand/TRAP, murine recombi nant 4015 25 μg, 100 μg, 500 μg, 1 mg c-jun (1-79)-GST Fusion Protein 7001 100 μg ERK1, Active 7741 5 μg IGF-I, human recombinant 4119 100 μg, 1 mg, 5 mg, 10 mg, 20 mg, 50 mg, 1 g IL-1 alpha, human recombinant 4125 10 μg, 50 μg, 1 mg IL-1 alpha, murine recombinant 4126 10 μg, 50 μg, 1 mg IL-1 alpha, rat recombinant 4127 10 μg, 1 mg IL-1 beta, human recombinant 4128 10 μg, 50 μg, 1 mg IL-1 beta, rat recombinant 4130 10 μg, 50 μg, 1 mg MAPKAPK2, Active 7737 5 μg MAPKAPK3, Active 7755 5 μg NGF-beta, human recombinant 4303 20 μg, 1 mg NGF-beta, human recombinant 4303R 20 μg, 100 μg, 1 mg NGF-beta, murine recombinant 4304 5 μg, 20 μg, 100 μg, 1 mg p38alpha, Active 7756 5 μg p38beta, Active 7763 5 μg, 100 μg 3

Enzymes P38delta, Active 7754 5 μg PAK4, Active 7707 5 μg PAK7, Active 7727 5 μg PDGF-AA, human recombinant 4482 10 μg, 50 μg, 1 mg PDGF-AA, murine recombinant 4483 10 μg, 1 mg PDGF-AB, human recombinant 4485 10 μg, 50 μg, 1 mg PDGF-BB, human recombinant 4488 10 μg, 50 μg, 1 mg PDGF-BB, murine recombinant 4489 10 μg, 50 μg, 1 mg PDGFR beta, Active 7770 5 μg RAF1, Active 7726 5 μg, 100 μg RSK1, Active 7721 5 μg RSK2, Active 7768 5 μg RSK3, Active 7774 5 μg TNF-alpha, human recombinant 1050 10 μg, 50 μg, 1 mg TNF-alpha, murine recombinant 1051 10 μg, 50 μg, 1 mg TNF-alpha, rat recombinant 1052 10 μg, 50 μg, 1 mg TNF-beta, human recombinant 4345 20 μg, 1 mg Chemical Activators CAS Number Anisomycin 1549-10 10 mg 22862-76-6 MAP Kinase/MEK Inhibitors CAS Number 7,3',4'-Trihydroxyisoflavone 1886 25 mg, 100 mg 485-63-2 BIX02189 2670 1 mg, 5 mg 1094614-85-3 Doramapimod 1954 5 mg, 25 mg 285983-48-4 GSK-1120212 1960 1 mg, 5 mg 871700-17-3 GSK-2118436 mesylate 2800 5 mg, 25 mg 1195768-06-9 PathwayReady MAP Kinase Signaling Inhibitor Panel K862 7 inhibitors Multiple Inhibitors PD 98059 1666 5 mg 167869-21-8 EZSolution PD 98059 1783 5 mg 167869-21-8 PD-0325901 1643 2 mg, 5 mg, 25 mg 391210-10-9 EZSolution PD-0325901, Sterile-Filtered 1990 1 ml 391210-10-9 PD184352 1585 1 mg, 5 mg, 25 mg 212631-79-3 EZSolution PD184352 1871 1 mg 212631-79-3 SB 202190 2493 5 mg, 25 mg 152121-30-7 SB 203580 1712 1 mg, 5 mg 152121-47-6 EZSolution SB 203580 1786 1 mg 152121-47-6 Skepinone-L B1110 1 mg, 5 mg 1221485-83-1 4

MAP Kinase/MEK Inhibitors CAS Number SKF-86002 2894 5 mg, 25 mg 72873-74-6 Sorafenib 1594 25 mg, 100 mg 475207-59-1 TAK-733 2460 5 mg, 25 mg 1035555-63-5 U0126 1668 5 mg 109511-58-2 VX-702 1598 1 mg, 5 mg 745833-23-2 ZM 336372 1789 1 mg, 5 mg 208260-29-1 Please visit www.biovision.com for a comprehensive overview on our products! 5